Lumexa Imaging Holdings, Inc. Common Stock (LMRI) Stock
Key stats
- Market cap
- $1.53B
- Price / Earnings ratio
- -28.4x
- EPS (TTM)
- -$0.66
- Volume
- Loading
- 52-week high
- $19.45
- 52-week low
- $6.45
- Next earnings report
- 18 Nov 2026
Source: third-party data provider, as of November 13, 2026
Compare with LMRI
Recent news

Lumexa (LMRI) Upgraded to Buy: Here's What You Should Know
Lumexa (LMRI) Upgraded to Buy: Here's What You Should Know
LMRI

Wall Street Analysts See a 36.88% Upside in Lumexa (LMRI): Can the Stock Really Move This High?
Wall Street Analysts See a 36.88% Upside in Lumexa (LMRI): Can the Stock Really Move This High?
LMRI

Lumexa Imaging Q2 Earnings Call Highlights
Lumexa Imaging Q2 Earnings Call Highlights
LMRI

4 Medical Products Stocks Poised to Win Despite Industry Headwinds
4 Medical Products Stocks Poised to Win Despite Industry Headwinds
LMRI
Technical indicators
- RSI 14
- 86.11
- MACD 12/26/9
- 0.92
- EMA 9 of MACD
- 0.51
- MACD histogram
- 0.41
- SMA 50
- $11.33
- Price above SMA 50
- EMA 50
- $11.67
- Price above EMA 50
- SMA 200
- $11.04
- Price above SMA 200
- EMA 200
- $11.79
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market has no earnings per share expectations for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Lumexa (LMRI) Upgraded to Buy: Here's What You Should Know
Lumexa (LMRI) Upgraded to Buy: Here's What You Should Know
LMRI

Wall Street Analysts See a 36.88% Upside in Lumexa (LMRI): Can the Stock Really Move This High?
Wall Street Analysts See a 36.88% Upside in Lumexa (LMRI): Can the Stock Really Move This High?
LMRI

Lumexa Imaging Q2 Earnings Call Highlights
Lumexa Imaging Q2 Earnings Call Highlights
LMRI

4 Medical Products Stocks Poised to Win Despite Industry Headwinds
4 Medical Products Stocks Poised to Win Despite Industry Headwinds
LMRI

Wall Street Analysts Think Lumexa (LMRI) Could Surge 44.08%: Read This Before Placing a Bet
Wall Street Analysts Think Lumexa (LMRI) Could Surge 44.08%: Read This Before Placing a Bet
LMRI

Wall Street Analysts Believe Lumexa (LMRI) Could Rally 73.25%: Here's is How to Trade
Wall Street Analysts Believe Lumexa (LMRI) Could Rally 73.25%: Here's is How to Trade
LMRI

Lumexa Imaging Q1 Earnings Call Highlights
Lumexa Imaging Q1 Earnings Call Highlights
LMRI

Lumexa Imaging valued at $1.76 billion as shares edge up in Nasdaq debut
Lumexa Imaging valued at $1.76 billion as shares edge up in Nasdaq debut
LMRI

Welsh Carson-backed Lumexa Imaging raises $463 million in US IPO
Welsh Carson-backed Lumexa Imaging raises $463 million in US IPO
LMRI

Lumexa Imaging targets up to $1.89 billion valuation in US IPO
Lumexa Imaging targets up to $1.89 billion valuation in US IPO
LMRI
About Lumexa Imaging Holdings, Inc. Common Stock
Lumexa Imaging Holdings, Inc. (Nasdaq: LMRI) is a U.S. healthcare company and one of the largest national providers of outpatient diagnostic imaging services, operating a scalable network of imaging centers across multiple states to deliver advanced MRI, CT and other imaging exams
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Caitlin Zulla | CEO & Director | 1979 |
| Mr. Henry Lee Cooper | Executive Chairman | 1963 |
| Mr. J. Anthony Martin | Chief Financial Officer | 1972 |
| James E. Walker Jr. | Chief Accounting Officer | — |
| Mr. Lachlan Tidmarsh | Chief Information Officer | — |
| Mr. Paul Gilbert | Chief Legal Officer & Corporate Secretary | — |
| Ms. Jill Lewandowski | Chief People Officer | — |
| Dr. Russell Stewart M.B.A., M.D., M.S. | Chief Medical Officer | 1978 |
| Mr. Rick Grodin | Division President | — |
| Mr. Chris Robertson | Chief Revenue Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 86.11
- MACD 12/26/9
- 0.92
- EMA 9 of MACD
- 0.51
- MACD histogram
- 0.41
- SMA 50
- $11.33
- Price above SMA 50
- EMA 50
- $11.67
- Price above EMA 50
- SMA 200
- $11.04
- Price above SMA 200
- EMA 200
- $11.79
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $13.00
- Average
- $16.33
- High
- $18.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -0.1 | |||||||||||
| 2026 | -30.2 | +15.3 | -45.8 | +1.8 | -22.2 | +53.5 | -10.2 | +3.6 | -11.9 | +13.0 | +43.0 |



